

[Lisinopril + hydrochlorothiazide](#)

Essential medicine status

Section:

[12. Cardiovascular medicines](#) [12.3. Antihypertensive medicines](#)

ATC codes: [C09BA03](#)

Indication

Essential hypertension ICD11 code: [BA00.Z](#)

INN

Lisinopril + hydrochlorothiazide

Medicine type

Chemical agent

List type

Core

Formulations

**Oral > Solid:** 10 mg + 12.5 mg ; 20 mg + 12.5 mg ; 20 mg + 25 mg

EML status history

Application rejected in 2017 ([TRS 1006](#))

Added in 2019 ([TRS 1021](#))

Changed in 2021 ([TRS 1035](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

Medicines within the same pharmacological class can be used

Therapeutic alternatives limitations

Therapeutic alternatives are medicines in the 4th level ATC chemical subgroup C09AA ACE inhibitors, plain (for lisinopril); and chlorothiazide, chlortalidone and indapamide (for hydrochlorothiazide)

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Lisinopril + hydrochlorothiazide](#)

[DrugBank](#)

[Lisinopril](#),

[Hydrochlorothiazide](#)

Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended that fixed-dose combinations of medicines in 4th level ATC chemical subgroup, C09AA ACE inhibitors, plain (for lisinopril) and chlorothiazide, chlortalidone and indapamide (for hydrochlorothiazide), be specified as therapeutic alternatives under the square box listing for lisinopril + hydrochlorothiazide on the EML.